Amryt Pharma Share Price (AMYT)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Amryt Pharma	LSE:AMYT	London	Ordinary Share	GB00BDD1LS57	ORD 1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+0.00p	+0.00%	12.50p	16,759	08:00:00

Bid Price		Offer Price	High Price	Low Price	Open Price
12.20p		12.80p	12.50p	12.50p	12.50p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	11.36	-23.23	-10.42		27.1

Related Shares
AstraZeneca (AZN), GlaxoSmithKline (GSK), Venn Life (VENN), Port Erin (PEBI)

Amryt Pharma (AMYT) Latest News

Amryt Pharma News

Date	Time	Source	Headline
17/10/2018	10:43	ALNC	Amryt Pharma Agrees Lojuxta Reimbursement Deal With French Regulator
17/10/2018	06:43	ALNCF	Alliance News Flash Headline
17/10/2018	06:00	UKREG	Amryt Pharma PLC Lojuxta to be reimbursed in France
26/9/2018	11:47	ALNC	Amryt Narrows Half Year Loss On Lojuxta Sales And Lower Expenses
26/9/2018	06:01	UKREG	Amryt Pharma PLC Interim Results
14/9/2018	06:01	UKREG	Amryt Pharma PLC Notice of Results
10/9/2018	10:54	ALNC	Amryt Pharma Receives FDA Investigational New Drug Approval For AP101
10/9/2018	06:00	UKREG	Amryt Pharma PLC Amryt receives IND approval from FDA for AP101
02/8/2018	11:15	ALNC	Amryt Pharma Gets Rare Pediatric Disease Designation For AP101
02/8/2018	06:00	UKREG	Amryt Pharma PLC FDA grants Pediatric Rare Disease designation

More Amryt Pharma News

Amryt Pharma Takeover Rumours

Amryt Pharma (AMYT) Share Charts

1 Year Amryt Pharma Chart

1 Month Amryt Pharma Chart

Intraday Amryt Pharma Chart

Amryt Pharma (AMYT) Discussions and Chat

Amryt Pharma Forums and Chat

Date	Time	Title	Posts
16/11/2018	23:25	Amryt Pharma	3,677
14/7/2018	16:11	AMRYT Bio-Pharma R&D	1
27/3/2017	07:19	Amryt Pharma	108
21/4/2016	09:07	AMYT	1
21/4/2016	09:04	Amryt Pharma	2

Add a New Thread

Amryt Pharma (AMYT) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2018-11-16 08:07:10	12.30	4,250	522.71	O
2018-11-16 08:00:28	12.29	9,607	1,180.70	O
2018-11-16 08:00:28	12.29	1,020	125.36	O
2018-11-16 08:00:15	12.29	1,882	231.30	O

View all Amryt Pharma trades in real-time

Amryt Pharma (AMYT) Top Chat Posts

Date	Subject
16/11/2018 08:20	Amryt Pharma Daily Update: Amryt Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AMYT. The last closing price for Amryt Pharma was 12.50p. Amryt Pharma has a 4 week average price of 12.35p and a 12 week average price of 12.35p. The 1 year high share price is 21.88p while the 1 year low share price is currently 12.35p. There are currently 216,839,632 shares in issue and the average daily traded volume is 151,867 shares. The market capitalisation of Amryt Pharma is £27,104,954. Read Full Thread Reply
16/10/2018 19:14	papillon: Bronxville Posts: 529 Opinion: No Opinion Price: 14.875 RE: Kinda make AP101 obsolete Today 15:31 Well I'm glad I'm not heavily involved anymore but I'm convinced now these guys are peeing money down the drain.. Krystal's trial was tiny but a complete closure of wounds in 2 weeks is impressive.Who cares about the placebos if the actual trial is a 100% successful.The market is liking the results as well... If AMYT is forced to make the trial larger then they will have to dilute again.. Amryt dont have a hope in hell of finding other orphan pharmaceutical companies to partner with them due to their cash burn..Someone said 'too many high paid snouts in the trough' for such a small company.. I think Cathal Friel saw the writing on the wall and took what he could at the time... >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Yes the wound healing time of KB103 was impressive, but it was just a 2 person trial. So many drugs sail through phase 1 & phase 2, but fail phase 3, either because they prove to be ineffective (futile), or worse still they prove to be dangerous and unsafe when the trial size is much, much, bigger than just 2 patients. Both FARN & IMM had drugs/treatments that sailed through phase 1 & 2 yet failed phase 3 with catastrophic effects on their respective sp's. Ask volsung, a poster on this bb, who had (unfortunately) shares in IMM. Regarding Jacksonpollacks comment about too many "snouts in the trough" he also says that about EDL. It's one of his common observations on AIM shares he holds, or has held. He specifically mentions the AMYT BoD, but there are only 2 execs on the BoD with their "snounts in the trough". There are 4 non execs on the BoD, but they can't be accused of having their "snouts in the trough". There are a further 6 members of the senior management team and they could have their "snouts in the trough" Cathal Friel could well have seen the "writing on the wall", but he still has 24 million, 697 thousand and 347 shares (24,697,347). That's 8.99% of AMYT shares in issue. According to the RNS dated 8th May 2018 he has signed a 2 year LOCK IN for those 24,697,347 shares after selling 8.38 million @ 17p per share. So, Bronxville, Cathal Friel still has a lot of skin left in the AMYT game! He's still got 75% of his original AMYT shareholding and has agreed that he can't sell them for around 18 months. Like you Bronxville I have no idea of what the EASE interim analysis, expected in December, will contain. I suggest we wait and see what the results of the analysis are and what recommendations are made. PS. Congratulations on your recent investment in Krystal Biotech, Bronxville. It's been very profitable. There's no doubt that investors liked the KB103 trial news, even though it was just a 2 person trial. I suspect that if Krystal Biotech were listed on AIM (like AMYT) instead of Nasdaq then it's share price and hence Mkt Cap would be much lower than it currently is. Read Full Thread Follow Reply
12/9/2018 12:30	papillon: Yes, greendragon, but if the interim analysis proves to be inconclusive the share price would be a lot lower as a consequence. If then the interim analysis was inconclusive and AMYT decided to carry on with the trials, but to increase their size and scope then cash would need to be raised, but with a much lower share price. A placing at a much lower share price would be harder to get away and lead to much greater dilution. Would AMYT be prepared to take that risk? Of course I have no knowledge of the current AMYT cash position and I have no idea of what AMYT intends to do with regards to it. My reason for continuing to hold my 25k of AMYT shares is I'm prepared to gamble my circa £5k of cash on a positive interim analysis. I don't know the odds on success, or failure. PS. AMYT might well be "confident of positive interims", but I presume they don't know how they are progressing because they are being conducted under independent supervision. In theory the interim results will be as unknown to AMYT as to us small shareholders; whether that's true in practice I have no idea. Perhaps AMYT do already know the conclusions of the interim analysis in advance? Perhaps data is being "leaked" to AMYT? Who knows? Read Full Thread Follow Reply
15/7/2018 13:30	papillon: That Sunday Times article: SABAH MEDDINGS: INSIDE THE CITY Amryt Pharma, the drugs minnow with big ambitions Sabah Meddings July 15 2018, 12:01am, The Sunday Times Music Health United States Pharmaceutical minnows are setting their sights on the 7,000 rare diseases for which there are often no cures ALAMY Share Save Once upon a time, the easiest way to make money in healthcare was to develop a remedy for heart disease or depression. Marginal improvements in patients’ symptoms meant the drugs company was on to a winner — a “blockbuster” product was within its grasp. Today a new band of pharmaceutical minnows are setting their sights on the 7,000 rare diseases for which there are often no cures. The regulatory process for getting these drugs to market can be quicker because this field is often ignored by the sector’s big players. One such company is Amryt Pharma, based in Dublin and listed on AIM. Founder and chief executive Joe Wiley conceived the idea of “commercialising” treatments for rare diseases that had been developed by others — thus removing the cost and risk of early-stage drug development. Amryt already has a product on the market in several countries. Last week, the company won approval for Lojuxta, a treatment for a rare genetic disorder that raises cholesterol levels, to be prescribed by the NHS. Amryt bought the rights to sell Lojuxta outside the US in December 2016. It has since grown sales from €7m to €12m (£10.6m). By 2023, they are expected to reach €34m. Here is where Amryt becomes more interesting. Analysts say the company’s 16p share price, which values it at £44.1m, is based on Lojuxta alone. However, Amryt has another treatment in development — and it is on the lookout for others. Interim analysis on Episalvan, which is currently in late-stage trials, is due to be published towards the end of this year. The gel is used to treat epidermolysis bullosa, a skin condition for which there is no cure. Those born with the disorder are known as butterfly children because everyday activities — even putting on socks — can cause extreme skin wounds. Episalvan is already approved to treat minor wounds in adults, but Amryt is testing it in what should be a more lucrative market. It is sensible to be cautious when investing in companies that have a long way to fall if their treatments fail to impress in clinical trials. Yet shares in Amryt have under-performed since it floated. Amryt has ambitious plans for Lojuxta, which it is expanding into other markets. Also, the company has the expertise of Harry Stratford, founder of biotech giant Shire, who is the chairman. If it continues to deliver on its promises and wins approval for Episalvan, Amryt should be an attractive long-term investment. Buy. @sabahmeddings hTTps://www.thetimes.co.uk/edition/business/amryt-pharma-the-drugs-minnow-with-big-ambitions-5qfkqqlh8 PS Bermudashorts, you need to change the tt's to capital TT's (hTTp) otherwise the advfn sftware automatically changes the tt's to xx's so the link can't be accessed. PPS. I don't know how many share buying PI's investing in AIM shares read the Sunday Times, but it's likely the MM's will open the AMYT share price higher first thing Monday morning when the Mkt opens at 8am Read Full Thread Follow Reply
17/6/2018 11:50	papillon: "If the business's valuation is justified by Lojuxta alone then if AP101 fails the share price shouldn't fall in theory......but I suspect the share price will fall by between 30% and 50% at least initially." Analysts reckon the current AMYT Mkt Cap is "justified by Lojuxta alone", greendragon. They might be right, but then again they might be wrong. Don't forget some of those analysts receive money from AMYT, so they are not unbiased. There must be a signiicant portion of the current Mkt Cap attached to the EASE phase III trial so if analysts feel that the current Mkt Cap is "justified by Lojuxta alone" then either AMYT is seriously undervalued at the current Mkt Cap, or investors don't believe the analysts! I think you are correct in that if it's cosidered futile to continue with the EASE phase III trial then the AMYT share price will plummet. We wont know current Lojuxta revenue figures until the interim results are issued in September and the latest on the EASE phase III trial until October (probably). There's always the possibilty of a "wild card" RNS being issued between now and September concerning another Lojuxta type licensing deal. I have no idea of the likelihood that happening. It could be very low for all I know. As far as I'm concerned my circa £5k investment in AMYT is a punt. A gamble, but one I'm prepared to make. If the gamble comes off I'll be delighted; if it doesn't, that's life! Read Full Thread Follow Reply
19/5/2018 13:48	papillon: Bronxville Posts: 243 Off Topic Opinion: No Opinion Price: 17.35 RE: Friel's buy...32p in today's m..Today 00:00 £692,000 in Friels cold hard cash spent. Why is he selling at .17 now? Why Open Orphan? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> True, Bronxville, but what you're CONVENIENTLY FORGETTING is he only bought 2.6m AMYT shares @ 32p (via the 20.8m FAST shares he bought @ 4p) OUT OF A TOTAL of 33m AMYT shares he held until he sold 8.38m recently @ 17p. It's easy enough to check, but I suspect that FRIEL'S AVERAGE COST per AMYT share was MUCH LESS THAN 10p, Bronxville, since many of his 33m AMYT shares were acquired for NEGLIGABLE (or ZERO) cost due to his being one of the founders of AMYT. HENCE, Bronxville, I suspect Friel could sell ALL of his 33m shares @ 17p and still make a magnificent profit. I wouldn't be surprised if he doubled his money (at least) @ 17p compared to his AVERAGE buying price. You need to stop prattling on about the shares Friel bought @ the equivalent of 32p because it was only a small percentage of his 33m shares and the AVERAGE cost to him would likely be less than 10p. Lots of LOVE, papillon! :-) PS. I see Bronxville has filtered me. Not that I'm worried as I don't post on the lse bb's. PPS. Bronxville is digging up as much dirt as he can, even if the link to AMYT is tenuous. Good luck to him, because no one will take the slightest notice of him. NEWS drives share prices, not anonymous posters on bb's. Will the AMYT share price go towards £1, or 1p, during the next 12 months? IT ALL DEPENDS ON THE NEWS AMYT RELEASES AND WHETHER INVESTORS BELIEVE THAT NEWS, OR NOT. I can GUARANTEE that Bronxville will have absolutely NO influence on the direction of the AMYT share price over the next 12 months. Bronxville is SORE with Friel & AMYT because he bought FAST shares at a high price and consequently LOST a lot of his money when he bailed out of AMYT. That's understandable. He's a VERY SORE LOSER! Read Full Thread Follow Reply
18/5/2018 22:13	papillon: Bronxville Posts: 239 Off Topic Opinion: No Opinion Price: 17.35 A little memory loss Paps Today 21:35 11/8/2015 21:37 papillon: Friel could be feathering his nest, Asturius101, but he's showing a funny old way of going about it since he paid almost double the price recently to acquire over 18m FAST shares (he paid 4p per share when the then share price was 2.25p)!! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Sorry Bronxville. There's NOTHING wrong with my memory! However there is something wrong with yours! You're NOT using your little grey cells. Cathal Friel had just over 33m AMYT shares. He has sold 8.38m and now has circa 24.67m. http://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-PLC-Holdings-in-Company-and-Lock-in-a/77363966 Cathal Friel ended up with 39.75m shares in FAST in July 2015 after buying circa 20.85m FAST shares @ 4p (4p was then a very large percentage premium to the then quoted FAST sp). He bought those shares to stop the owners from blocking his bid to turn FAST into a biotech via an RTO. He had to pay way over the odds. I know all this because I bought my first FAST shares early in 2015 because of the large percentage discount that the shares were trading at compared to their cash. http://uk.advfn.com/stock-market/london/fastnet-equity-FAST/share-news/Fastnet-Oil-Gas-PLC-Director-PDMR-Shareholding/67572254 http://uk.advfn.com/stock-market/london/fastnet-equity-FAST/share-news/Fastnet-Oil-Gas-PLC-Director-PDMR-Shareholding/67475086 If you divide those 20.85m FAST shares by 8 you get the the equivalent number of AMYT shares that, in practice, Friel paid 32p for. That works out at circa 2.6m AMYT shares that, in effect, Friel paid 32p for. Yet until the start of this month Friel had just over 33m AMYT shares. Hence the AMYT shares he paid the equivalent of 32p for was less than 10% of his total holding!! Yet you, Bronxville, in your posts like to give the impression that all of Friel's AMYT shares cost the equivalent of 32p. WHY, is the question I ask? Is it because your memory is failing, or are you deliberately muddying the waters by giving a false impression? Even if you take the total number of FAST shares that Friel held (39.75m) and then convert them into AMYT shares (divide by 8) you get circa 5m AMYT shares. Yet Friel had just over 33m AMYT shares. Hence the total FAST shares held by Friel when converted into AMYT shares only comprised around 15% of his total holding in AMYT shares. In other words, Einstein (sorry, Bronxville) circa 28m of Friel's total holding of circa 33m AMYT shares (around 85%) had NO connection with his holding in FAST. So, in effect, Cathal Friel has sold 8.38m AMYT shares @ 17p from the 28m he acquired directly in AMYT (not via FAST). Some of those 28m shares were founders shares (and were no doubt acquired at no, or negliable, cost), whilst the remainder were acquired via the original placing. However members of the "concert party" (of which Friel was obviously one) did NOT pay 24p for their shares. They got their shares at a sizeable discount. Circa 16p was the price they paid. So by selling 8.38m AMYT shares @ 17p Cathal Friel has still made a profit (if the shares he sold could be considered to be "founders" shares then he made almost all profit because they were acquired at no, or negligable, cost to him). Presumably when he comes to sell his remaining 24.67m shares he will hope to make another profit. If the AMYT share price is above 32p when he next sells some (in 12 months time) he will definitely make a profit on them!!. :-) PS. You really must start posting the whole story, Bronxville and not just that part of the story that suits your agenda. You asked JimbobTechstock "You wouldn't happen to know (Cathal) personally would you." The funny thing is I was thinking of asking you the same question, but about Joe Wiley! LOL. I have wondered if you knew him and had a grudge against him. :-) Read Full Thread Follow Reply
12/12/2017 17:09	papillon: Bronxville Posts: 62 Off Topic Opinion: No Opinion Price: 20.125 RE: Wiley,Nealon Today 15:50 Yep the market is on to the sleezy antics of this management team. Options should have been at .30 cents.. Wiley basically just gave himself a £400 thousand bonus! For What? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> How has Wiley given himself a £400k bonus, Bronxville? Stop spouting unadultered rubbish. He HASN'T been given 2.061m shares. He's been given OPTIONS to acquire 2.061m shares. BIG DIFFERENCE. For all we know the AMYT share price will stay below the 20.12p subscription price (hope it doesn't, LOL) in which case he wont ever exercise that option to buy. This is AIM and AMYT still has a £55m Mkt Cap. There is NO guarantee that AP101 will be successful and there is NO guarantee that those who know how the phase 3 trial is progressing wont take advantage of that knowledge by selling, shorting, in the market. Not saying that will happen, but hey, who knows? I'm not against options per se, but the option price should have been much higher than the actual 20.12p. Perhaps 40p. That would have been an incentive. EDIT: For your information, Bronxville, Wiley will have received a £400k bonus from the BoD if the AMYT share price reaches 40p. Will it? Who can tell? I hope so, but I wouldn't bet my house on it happening. This is AIM after all and AMYT is very spculative. I've had a £4k gamble on AMYT, which I might push up to a maximum of £5k, but that's not definite. I definitely wouldn't go above £5k. I'm not rich enough to gamble more than £5k; after all I wouldn't bet £5k on a horse race, but some do! Read Full Thread Follow Reply
14/11/2017 16:54	papillon: Bronxville Posts: 21 Off Topic Opinion: No Opinion Price: 18.125 RE: Slide Today 15:12 Management are a disgrace... I have never seen so many rookie mistakes starting with the share price drop from .24 in the original reverse merger.Not to mention blatently misleading shareholders on companies valuation. Ineptitude!! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOL. LOL. Bronxville is the disgrace! Management are doing their job. The share price is dictated by short term traders! The job of management is to open up new markets for Lojuxta and progress the trials for AP101 & AP102. They seem to be doing that. Investors, especially short term traders, dictate the share price!!!!!!!!!! Obviously the recent placing was bad news for the AMYT share price in the short term. Why the BoD decided that the time was right to raise more cash is open to question. I don't think it affects AMYT prospects in the medium & longer term; Lojuxta sales and the trial results will determine the AMYT share price in the medium & longer term. Read Full Thread Follow Reply
04/11/2016 16:22	papillon: It's proving to be a very slow death for the AMYT share price in the continuing absence of good news (in fact any news!) from the company. I seem to remember the intraday low was around 14-14.25p back in early July. Will a retest of that low encourage bottom fishing buyers again, or will the AMYT share price continue it's descent into oblivion? Answers on a postcard please! LOL. Is AMYT worth a bottom fishing buy I wonder when it's below 15p? Read Full Thread Follow Reply
19/8/2016 18:29	papillon: dingo75 16 Aug'16 - 13:26 - 295 of 302 1 0 papp lol egg on your FACE! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOL. I'm always ending up with egg on my face, dingo75. However I still believe we will see a small, short term, fall back in the AMYT share price and then the formation of a bullish Inverse Head & Shoulders. You could be right and I will be proved wrong and end up with egg on my face, but I'm hopeful I will soon be proved right. After all a bullish chart formation, after a period of a falling share price, is often the sign that a significant price reversal and subsequent major share price rise is on the cards. Don't throw any more raw eggs at me just yet, dingo75, but keep them ready! LOL. Read Full Thread Follow Reply

Amryt Pharma share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:33 V: D:20181117 02:20:15